FMT
represents the first entry in an emerging new class of drugs:
microbiota
therapeutics. As a complex drug, FMT is appropriately
regulated
by the FDA Office of Vaccines, Blood, and Biologics in the
United
States. Unlike probiotics, which are scientifically defined
as
live microorganisms that benefit human health, microbiota
therapeutics
explicitly target disease. FMT relies on established
microbial
communities designed by nature over millions of years
and
tested for decades in individual donors, establishing a very high